Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „etravirine“
Suchtreffer
Begriffe & Kennungen
Aptivus · 4.5 · Concomitant use of Aptivus/ritonavir caused a decrease of etravirine exposure that could significantly impair
Eintrag öffnenCelsentri · 4.5 · 10 Etravirine and Maraviroc AUC12: ↑ 3.10 CELSENTRI dose should darunavir/ritonavir Maraviroc Cmax: ↑ 1.77 be
Eintrag öffnenCelsentri · 4.5 · Ritonavir AUC12: ↔ 0.93 Ritonavir Cmax: ↔ 1.02 Ritonavir C12: ↓ 0.74 Etravirine and Not studied. Based on the
Eintrag öffnenCelsentri · 4.5 · Ritonavir AUC12: ↔ 0.93 Ritonavir Cmax: ↔ 1.02 Ritonavir C12: ↓ 0.74 Etravirine and Not studied. Based on the
Eintrag öffnenCresemba · 4.5 · (CYP3A4/5 induction) Etravirine Not studied. The concomitant administration (moderate CYP3A4/5 inducer) Isavuc
Eintrag öffnenCresemba · 4.5 · (CYP3A4/5 induction) Etravirine Not studied. The concomitant administration (moderate CYP3A4/5 inducer) Isavuc
Eintrag öffnenDovato · 4.5 · Darunavir Ritonavir Etravirine Efavirenz/Dolutegravir Dolutegravir The recommended dose of dolutegravi
Eintrag öffnenDovato · 4.5 · Lopinavir Ritonavir Etravirine Darunavir+ritonavir+etravirine/ Dolutegravir No dose adjustment is nece
Eintrag öffnenEtravirine
Eintrag öffnenIntelence · 4.5 · 13 IMMUNOSUPPRESSANTS Cyclosporin Not studied. Etravirine is expected to decrease Co-administration with Sirol
Eintrag öffnenIntelence · 4.5 · 6 induce CYP3A4, CYP2C9 or CYP2C19 may increase the clearance of etravirine, resulting in lowered plasma conce
Eintrag öffnenIntelence · 4.5 · 9 Integrase Strand Transfer Inhibitors Dolutegravir dolutegravir Etravirine significantly 50 mg once daily AUC
Eintrag öffnenIntelence · 4.5 · Etravirine is a weak inducer of CYP3A4. Co-administration of etravirine with medicinal products primarily meta
Eintrag öffnenIntelence · 4.5 · Etravirine is metabolised by CYP3A4, CYP2C9 and CYP2C19 followed by glucuronidation of the metabolites by urid
Eintrag öffnenIntelence · 4.5 · Interactions between etravirine and co-administered medicinal products are listed in table 2 (increase is indi
Eintrag öffnenIntelence · 4.5 · Medicinal products that affect etravirine exposure
Eintrag öffnenIntelence · 4.5 · Medicinal products that are affected by the use of etravirine
Eintrag öffnenIntelence · 4.8 · 16 incidence of rash was higher in women compared to men in the etravirine arm in the DUET trials (rash ≥ grad
Eintrag öffnenIntelence · 4.8 · Adverse reactions reported in patients treated with etravirine are summarised in Table 3. The adverse reaction
Eintrag öffnenIntelence · 4.8 · Table 3: Adverse reactions observed with etravirine in clinical trials and post-marketing experience System Or
Eintrag öffnen